05-02-Daily AI News Daily

Daily Summary

The most essential read today is the novel longevity drug SRN-901, which uses multi-target intervention on aging pathways to extend both lifespan and healthspan.
Multi-target combination interventions (SRN-901 simultaneously targets four pathways) and drug repurposing are accelerating in parallel, signaling that single-target narratives are outdated.
If you can only follow one additional thread, continue tracking multi-omics reveals losartan's metabolic rejuvenation mechanism in aged mice and pre-frail older men.

⚡ Quick Navigation

  • 📰 Today’s AI Longevity Science News - Start with “Novel Longevity Drug SRN-901 Uses Multi-Target Intervention on Aging Pathways to Extend Lifespan and Healthspan,” then follow up with “Multi-Omics Reveals Losartan’s Metabolic Rejuvenation Mechanism in Aged Mice and Pre-Frail Older Men”

💡 Tip: Want early access to the latest AI models mentioned in this content (Claude 4.5, GPT, Gemini 3 Pro)? No account? Grab one at Aivora —one-minute setup, worry-free support.

Today’s AI Longevity Science News

👀 One-Liner

A common blood pressure drug triggered “metabolic rejuvenation” in older adults—drug repurposing’s longevity logic now has multi-omics-level hard evidence.

🔑 3 Key Takeaways

#DrugRepurposing #MultiTargetAgingIntervention #InflammatoryAgingMechanism

🔥 Top 6 Highlights

1. Novel Longevity Drug SRN-901 Uses Multi-Target Intervention on Aging Pathways to Extend Lifespan and Healthspan

The old playbook for longevity drugs: everyone bet on single targets—either clear senescent cells, activate autophagy, or boost NAD+. SRN-901 flips the script: it bundles mTOR inhibition, autophagy activation (cellular self-cleaning), NAD+ supplementation (energy metabolism core), mitochondrial autophagy (clearing damaged mitochondria), and senolytics (senescent cell clearance) into one molecule, hitting all at once. Study results show it simultaneously extended both lifespan and healthspan in animal models. Multi-target synergistic aging intervention is the next-phase competitive frontier in this space—worth tracking long-term.

2. Multi-Omics Reveals Losartan’s Metabolic Rejuvenation Mechanism in Aged Mice and Pre-Frail Older Men

Losartan is a decades-old, dirt-cheap blood pressure drug—safe, billions taking it globally. But this paper, just published yesterday, re-examined it through multi-omics (simultaneous analysis of genes, proteins, metabolites across multiple layers) and found it triggered systemic “metabolic rejuvenation” in aged mice and frail older men—not just blood pressure control, but molecular-level reversal of some aging hallmarks. Co-authors include Luigi Ferrucci, a core figure at NIA (National Institute on Aging), so clinical translation potential is real. An old drug almost anyone can get prescribed might be hiding longevity mechanisms we haven’t fully decoded yet.

3. p21⁺TREM2⁺ Senescent Macrophages Drive Inflammaging and Metabolic-Associated Fatty Liver Disease

Your liver harbors a battalion of “veteran” immune cells that stopped working normally but keep pumping out inflammatory signals, dragging neighboring cells into senescence. This paper pinpoints p21⁺TREM2⁺ senescent macrophages as key drivers of inflammaging (chronic low-grade inflammation fueling aging) and metabolic fatty liver. The payoff is direct: a concrete new target for senolytics, plus an explanation for why clearing senescent cells might simultaneously improve metabolic disease. Fatty liver + aging + immunity—three threads converge here.

4. Bidirectional Association Between Biological Aging and Cardiovascular Health—INSPIRE-T Lifespan Cohort Study

“Poor cardiovascular health → age faster”—everyone knows that direction. But the reverse? INSPIRE-T cohort research delivers a more complex answer: biological age (actual body aging rate) and cardiovascular health show bidirectional association—higher biological age means higher cardiovascular risk; conversely, cardiovascular status also shapes your biological age trajectory. Major implications for clinical use of biological age clocks: it’s not just a “measurement tool,” but potentially an early warning indicator of cardiovascular intervention effectiveness. Cohort-level evidence beats single-mechanism studies by a tier.

5. Immunosenescence in Lung Disease: Mechanistic Insights and Clinical Intervention Progress

Lung cancer, pulmonary fibrosis, COPD, long COVID—these seemingly different lung diseases share a common aging driver: immunosenescence (immune system decline with age). This review systematically maps how immunosenescence operates in lung disease and catalogs existing clinical evidence for senolytics and other interventions. For readers tracking the aging-chronic disease intersection, this is a “map-type” paper—threading scattered research into one clear logical chain, high archival value.

6. Toward Translatable Human Aging Interventions—12th ARDD Conference Review (2025)

ARDD (Aging Research and Drug Discovery Conference) is the field’s premier annual gathering. The 2025 12th edition review just dropped, author roster reads like an aging research “hall of fame”—Ana Maria Cuervo, Anne Brunet, Bente Klarlund Pedersen and other top scholars all in. Core theme: “From mechanism research to translatable human aging interventions,” spanning autophagy, epigenetic reprogramming, exercise intervention, senescent cell clearance and more. Want to quickly grasp the field’s 2025 progress? This paper saves you reading dozens—it’s the fastest entry point.

📌 Worth Watching

[Research] Novel Longevity Drug SRN-901 Uses Multi-Target Intervention on Aging Pathways to Extend Lifespan and Healthspan — mTOR + NAD+ + senolytics + mitochondrial autophagy all firing together—this combo is rare in literature, follow human trial milestones closely.

[Research] Multi-Omics Reveals Losartan’s Metabolic Rejuvenation Mechanism in Aged Mice and Pre-Frail Older Men — Ferrucci is NIA core faculty; his research typically has strong clinical translation potential. Drug repurposing pathway has low cost, solid safety data.

[Research] Bidirectional Association Between Biological Aging and Cardiovascular Health—INSPIRE-T Lifespan Cohort Study — Bidirectional design strengthens conclusions, provides cohort-level backing for biological age clocks as cardiovascular clinical indicators.

😄 AI Longevity Science Fun Fact

Multi-Omics Reveals Losartan’s Metabolic Rejuvenation Mechanism in Aged Mice and Pre-Frail Older Men

Sometimes science’s plot twists are pure theater: Losartan quietly worked in cardiology for decades—nobody thought it had anything to do with “living longer.” Then researchers re-scanned it with multi-omics and found it was secretly doing something huge in older adults—metabolic-level rejuvenation. Like discovering your twenty-year-old rice cooker also purifies air. The researchers probably didn’t expect a blood pressure drug paper to get this much heat from the longevity crowd.

🔮 AI Longevity Science Trend Predictions

Multi-Target Aging Intervention Drugs Will Become Next Funding Wave Hotspot

Drug Repurposing Research in Aging Will Notably Accelerate

Senolytics in Metabolic Disease (Fatty Liver, Diabetes) Clinical Trials Will Increase

Biological Age Clocks Will Be Incorporated as Secondary Endpoints in Cardiovascular Clinical Trials

❓ Related Questions

Where can I continuously track the latest research on multi-target longevity drugs and aging interventions?

Multi-target aging intervention (simultaneously targeting mTOR, NAD+, senolytics, mitochondrial autophagy and other pathways) is currently the most active frontier in longevity research, with high-frequency paper and clinical trial updates—manual PubMed searching easily misses critical nodes. Key changes worth monitoring: new drugs entering human trials, breakthrough publications in top journals, and multi-omics re-interpretation of existing drugs in aging.

Recommended: Visit AI Longevity Science Daily for curated daily updates on longevity, lifespan extension, aging, biological age, aging interventions and AI applications—skip the noise, save research time.

Last updated on
05-03-Daily05-01-Daily